Table 4.

Hydrogen bond formation between SARS-CoV M^pro active site residues and bound inhibitors of the selected complexes.

PDB Entry	Thr24	Thr25	Thr26	His41	Phe140	Asn142	Gly143	Ser144	Cys145	His163	His164	Met165	Glu166	Gln189	Thr190	Gln192
5RF6a		✓											✓
5RG0a		✓					✓	✓	✓
5RG3a	✓		✓
6LU7a					✓		✓			✓	✓			✓	✓
6Y2Fa				✓	✓		✓		✓		✓		✓
6Y2Ga				✓	✓		✓	✓	✓		✓		✓
1UK4					✓		✓	✓					✓
1WOF									✓				✓	✓	✓
2A5I					✓	✓	✓	✓			✓		✓
2A5K					✓	✓	✓	✓	✓		✓		✓
2ACF
2ALV					✓				✓		✓		✓
2AMD									✓		✓		✓	✓
2AMQ									✓		✓		✓	✓	✓
2D2D													✓	✓
2GTB					✓	✓	✓	✓	✓		✓		✓	✓
2GX4					✓		✓						✓	✓
2GZ7															✓	✓
2GZ8						✓			✓
2HOB					✓				✓	✓	✓	✓	✓	✓	✓
2OP9				✓					✓				✓
2Z3C							✓	✓	✓		✓		✓	✓
2Z3D				✓	✓		✓				✓		✓	✓
2Z3E					✓	✓	✓	✓	✓				✓	✓
2ZU4					✓				✓		✓		✓	✓
2ZU5					✓				✓		✓		✓	✓
3ATW							✓		✓		✓		✓		✓
3AVZ							✓				✓		✓		✓
3AW0									✓				✓
3IWM											✓		✓
3SN8							✓		✓				✓
3SNA					✓		✓		✓				✓		✓
3SNB					✓				✓				✓		✓	✓
3SNC					✓				✓				✓
3SND									✓				✓
3SNE												✓	✓
3SZN					✓		✓				✓		✓
3TIT					✓		✓				✓		✓
3TIU					✓				✓		✓		✓	✓
3TNS					✓						✓		✓	✓
3TNT					✓		✓				✓		✓	✓
3V3M							✓						✓
3VB4					✓				✓		✓		✓	✓	✓
3VB5							✓		✓		✓		✓	✓	✓
3VB6					✓	✓			✓		✓		✓		✓
3VB7					✓		✓		✓		✓		✓	✓	✓
4MDS									✓				✓
6Y7M				✓	✓		✓		✓		✓		✓

^aRecently determined SARS-CoV-2 M^pro crystal structures.